ADAR1 Capital Management LLC Increases Stock Position in Ventyx Biosciences, Inc. $VTYX

Key Points

• ADAR1 Capital Management LLC increased its stake in Ventyx Biosciences by 126.1%, acquiring 157,070 shares for a total of 281,600 shares, valued at $324,000.
• Wall Street analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with a consensus price target of $7.50.
• Shares of Ventyx Biosciences opened at $2.40, after reporting earnings of ($0.38) EPS, exceeding analyst expectations by $0.07.

ADAR1 Capital Management LLC raised its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 126.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 281,600 shares of the company's stock after purchasing an additional 157,070 shares during the quarter. ADAR1 Capital Management LLC owned 0.40% of Ventyx Biosciences worth $324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Ventyx Biosciences by 376.4% in the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock valued at $9,359,000 after acquiring an additional 3,376,446 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Ventyx Biosciences by 15.9% in the 4th quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company's stock valued at $4,380,000 after purchasing an additional 275,000 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $3,903,000. Redmile Group LLC raised its position in Ventyx Biosciences by 1,164.1% during the first quarter. Redmile Group LLC now owns 1,569,793 shares of the company's stock worth $1,805,000 after acquiring an additional 1,445,615 shares during the period. Finally, Millennium Management LLC raised its position in shares of Ventyx Biosciences by 369.7% during the 4th quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock worth $2,807,000 after purchasing an additional 1,008,760 shares during the last quarter. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Trading Down 3.1%

VTYX stock traded down $0.08 during trading on Friday, hitting $2.52. 429,444 shares of the company's stock were exchanged, compared to its average volume of 569,336. The business has a 50-day moving average price of $2.65 and a two-hundred day moving average price of $1.93. The stock has a market capitalization of $179.70 million, a price-to-earnings ratio of -1.50 and a beta of 0.95. Ventyx Biosciences, Inc. has a 52-week low of $0.78 and a 52-week high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07. On average, equities research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Ventyx Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $7.50.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.